行情

IONS

IONS

伊奥尼斯制药
NASDAQ

实时行情|Nasdaq Last Sale

37.79
+0.31
+0.83%
盘后: 37.99 +0.2 +0.53% 18:34 06/18 EDT
开盘
37.20
昨收
37.48
最高
37.94
最低
36.56
成交量
225.14万
成交额
--
52周最高
64.37
52周最低
34.43
市值
53.27亿
市盈率(TTM)
-10.7367
分时
5日
1月
3月
1年
5年
The Daily Biotech Pulse:Hookipa、PDS Biotech 报告正面数据、Ironwood 首席财务官离职、Vertex 决策日
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 7)
Benzinga · 06/08 13:17
每日生物技术脉搏:默克、阿斯利康、诺华在 ASCO 的早期演讲者中,赛诺菲达成乳腺癌研究协议
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 3)
Benzinga · 06/04 13:39
每日生物技术动向:Biohaven,百时美施贵宝Squibb Snag FDA批准,Iterum UTI药品审查进展顺利,Centessa Pharmaceuticals首次在纳斯达克上市
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 27)
Benzinga · 05/28 12:02
每日生物技术动向:批准Vir-GlaxoSmithKline COVID-19抗体治疗,长期偏头痛药物数据的佐索诺加标,伊顿公司决定之日,2次IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 26)
Benzinga · 05/27 12:24
每日生物技术脉动:研究暂停后,Nabriva掌握数据,Larimar Wilts暂停,努力推迟监管备案
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 25)
Benzinga · 05/26 11:33
周二触及52周低点的股票
    Tuesday's morning session saw 16 companies set new 52-week lows.
Benzinga · 05/25 14:51
每日生物技术动向:辉瑞-BioNTech COVID-19订单流比比皆是,CMO Voyager首席执行官离任,Bristol-Myers Squibb的决策日,ASCO摘要移动股票
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 19)
Benzinga · 05/20 12:27
凯茜·伍德(Cathie Wood)几乎完全削减了苹果的股权—并购买了更多的Coinbase
Cathie Wood-led Ark Investment Management on Monday shed nearly all of its stake in Apple Inc (NASDAQ: AAPL) and continued to snap up shares of Coinbase Global Inc (NASDAQ: COIN).
Benzinga · 05/18 05:20
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解IONS最新的财务预测,通过IONS每股收益,每股净资产,每股现金流等数据分析伊奥尼斯制药近期的经营情况,然后做出明智的投资选择。
分析师评级

19位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测
分析师预测IONS价格均价为57.83,最高价位114.00,最低价为20.00。
EPS
机构持股
总机构数: 547
机构持股: 1.34亿
持股比例: 95.10%
总股本: 1.41亿
类型机构数股数
增持
126
720.07万
建仓
53
250.92万
减持
107
547.18万
平仓
64
201.56万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
-0.57%
制药与医学研究
-0.98%
高管信息
Chairman/Director
Joseph Loscalzo
Chief Executive Officer/Director
Brett Monia
Chief Financial Officer/Executive Vice President
Elizabeth Hougen
Executive Vice President/Chief Scientific Officer
C. Frank Bennett
Executive Vice President/General Counsel
Patrick O'Neil
Executive Vice President
Onaiza Cadoret-Manier
Executive Vice President
Richard Geary
Executive Vice President
Eugene Schneider
Executive Vice President
Eric Swayze
Other/Director
B. Lynne Parshall
Lead Director/Independent Director
Joseph Wender
Director
Allene Diaz
Independent Director
Spencer Berthelsen
Independent Director
Michael Hayden
Independent Director
Joan Herman
Independent Director
Joseph Klein
Independent Director
Frederick Muto
Independent Director
Peter Reikes
暂无数据
IONS 简况
Ionis Pharmaceuticals, Inc.(旧名:Isis Pharmaceuticals, Inc.)从事发现及开发核糖核酸靶向(RNA靶向)治疗剂。该公司通过两个业务部门运营:Ionis Core部和Akcea Therapeutics部。该公司的Ionis Core部正在开发一个药物发现平台。Akcea Therapeutics部运营其子公司,Akcea Therapeutics, Inc.。Akcea Therapeutics, Inc.从事开发及销售治疗心血管代谢疾病的药物。该公司正在开发旨在治疗罕见疾病患者的nusinersen、IONIS-TTR和volanesorsen等转型药物。除了三期项目,该公司还通过二期项目开发IONIS-FXI和IONIS-APO(a)-L等药物。Its Phase II pipeline包括治疗患有严重和罕见疾病、病毒感染、眼病、代谢紊乱和心血管疾病患者的药物。

微牛提供Ionis Pharmaceuticals Inc(NASDAQ-IONS)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的IONS股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易IONS股票基本功能。